← All trials
NCT03222206
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 8, 2017
- Primary completion
- Feb 22, 2019
- Completion date
- Feb 22, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 34
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Korea UniversityLead sponsor
- Kuhnil Pharmaceutical Co., Ltd.Collaborator
- Korea UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.